BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab
January 22, 2018 at 08:12 AM EST
* TEVA ANNOUNCES TOP-LINE RESULTS FROM PHASE III STUDIES OF SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA
